Quotes

The divestment of our OTC business represents a major change for Moberg Pharma and recognize the compelling value of both components of the business. Since April 1, 2019, Moberg Pharma has a fully funded business whose main goal is to make MOB-015 the future market leader in onychomycosis
Peter Wolpert, VD Moberg Pharma
I look forward to the opportunity to transition to a role as Executive Chairman while remaining close to the new management. After 13 intensive years as CEO of Moberg Pharma, it is important for me to be able to spend more time with my family, as well as continuing to contribute in a valuable way according to the company’s new needs
Peter Wolpert, CEO of Moberg Pharma AB
We are excited about this opportunity – being able to offer our shareholders a significant distribution while retaining the considerable upside of the fully funded MOB-015 program. The transaction enables us to increase the focus on making MOB-015 the future market leader in onychomycosis. I would also like to thank the OTC team for their exceptional contributions to Moberg Pharma over the past years and wish them continued success
Peter Wolpert, Moberg Pharma´s CEO
Completing the Phase 3 enrollment for MOB-015 is truly an important milestone. I am very grateful to the team for the hard work in completing the recruitment for both studies. More than 5,000 patients have been screened to recruit 800+ patients in the rigorous screening process, ultimately increasing the probability of strong phase 3 results for MOB-015
Peter Wolpert, Moberg Pharma’s CEO
As we conclude 2018, we’re pleased to report that EBITDA exceeded 100 MSEK for the first time. For MOB-015, patient screening for the European Phase 3 study was recently completed along with a second major license agreement, for Europe. The strong progress enabled today’s major event which realizes a premium value for our OTC business while indicating the significant value of MOB-015
Peter Wolpert, CEO of Moberg Pharma
We are excited to announce this transformational transaction. The transaction delivers exceptional value for the OTC-business and further validates the significant potential in MOB-015. The proceeds from this transaction offer near-term liquidity to our shareholders while preserving future upside. I would like to commend and thank our team for all of their hard work. Over the last few years we have acquired, built and generated superior performance for the company, and those efforts are reflected in this transaction
Peter Wolpert, CEO Moberg Pharma
After a thorough process, the board is convinced that the proposed transaction is the most attractive and brings significant value to the shareholders. The combination of a premium consideration for the OTC-business, specialized U.S. Healthcare investors entering at a premium valuation, while repaying outstanding debt, is highly attractive. Shareholders benefit from receiving a significant dividend while retaining the considerable upside of the MOB-015 program
Thomas Eklund, Chairman of the board at Moberg Pharma
We are thrilled to partner with Bayer for the European launch, as part of our vision of making MOB-015 the leading nail fungus treatment worldwide. This is the second major agreement for MOB-015 and a further validation of the significant market potential for our asset
Peter Wolpert, Moberg Pharma’s CEO
We are excited about the opportunity to partner with Moberg and the potential to bring this cutting-edge technology to market in order to advance one of our key categories
Heiko Petersen, Head of Bayer’s Global Category Business Unit Dermatology
It is a great pleasure to welcome Annica Magnusson and Gunilla Wengström to the Management Team at Moberg Pharma. Both Annica and Gunilla have assumed increasing senior responsibilities over the last year and I look forward to working together with them to continue to deliver on our strategy
Peter Wolpert, CEO of Moberg Pharma AB
Having been granted the Chinese patent means we now cover the main markets in which we are planning to commercialize MOB-015. It is an important milestone in our strategy to establish a broad patent protection for our proprietary products
Peter Wolpert, Moberg Pharma´s CEO
I’m very pleased with the continued momentum in our commercial operations as well as the progress for MOB-015 where we completed the enrollment for the North American phase 3-study and signed the first license agreement, confirming the market potential for our lead pipeline asset
Peter Wolpert, CEO of Moberg Pharma
We look forward to developing our relationship with Mundipharma and making Emtrix® available in new regions as we expand our footprint in growing markets
Peter Wolpert, Moberg Pharma´s CEO
This newly signed agreement with Moberg Pharma will give onychomycosis patients in MEA region access to one of the leading treatments for this common and uncomfortable nail fungal condition
Dr. Ashraf Allam, Vice President of Mundipharma META
The license agreement with Cipher Pharmaceuticals is a key step in preparing the global launch of MOB-015 and it confirms the significant market potential for our product. Cipher has excellent capabilities to make MOB-015 a success in Canada. We look forward to this exciting partnership and continue to progress commercialization plans in other key markets as we approach Phase 3 results
Peter Wolpert, Moberg Pharma´s CEO
We are excited at the prospect of bringing an innovative topical product to market that would be a provide a new safe and effective treatment option for the many Canadians who suffer from onychomycosis. The addition of MOB-015 represents our sixth transaction of the year and demonstrates the continued execution of our growth strategy as we build a pipeline of diversified and differentiated near term products for the Canadian market
Robert Tessarolo, President and CEO of Cipher
Completing the enrollment in North America is an important milestone and the result of excellent work from the team. I am very pleased with the progress and the rigorous screening process which increases the probability of strong phase 3 results
Peter Wolpert, Moberg Pharma’s CEO
We look forward to welcoming Shaw to Moberg Pharma. He will be joining the company in a highly exciting stage as we approach phase 3-results for MOB-015, where he will be adding valuable experience from the development, launch and commercialization of novel treatments
Peter Wolpert, CEO Moberg Pharma
Net revenue for the three key brands in the U.S. grew at record pace, fundamentally outpacing the market and strengthening our leading position in all key categories, while significantly increasing profitability. Meanwhile, MOB-015 studies are progressing according to plan with screening in North America recently completed
Peter Wolpert, CEO of Moberg Pharma
Over the past years, Mark Beveridge has played a key role in Moberg Pharma’s finance and transaction teams. It’s a pleasure to welcome Mark to the management team and I look forward to working together with him to continue developing Moberg Pharma’s operations
Peter Wolpert, CEO of Moberg Pharma
The year has begun with strong profitability and significant growth for all our key brands and the Phase 3 studies for MOB015 are progressing according to the November 2017 plan. For the first quarter, the company generated revenue growth of 5% adjusted for divested brands, despite currency headwind. In local currency, net revenue for our key brands grew by 12-17%. The EBITDA margin improved from 16% to 24%
Peter Wolpert, CEO of Moberg Pharma
This issuance of this patent in the United States is part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products and is an important milestone, as we now have granted patents in all territories where we have applied for patent protection.
Peter Wolpert, Moberg Pharma’s CEO
With extensive knowledge and experience, Kjell has contributed to the evolution of Moberg Pharma, especially through the development of Kerasal Nail® and MOB-015, where he has been instrumental. I’ve had the pleasure of working with Kjell since 2007 and I am highly grateful for his efforts over the years. I look forward to continuing our collaboration in his role as Senior Advisor to the company
Peter Wolpert, CEO Moberg Pharma
We are pleased with the divestment. We have now successfully divested most of our minor brands, enabling us to focus our resources on growing our larger brands
Peter Wolpert, CEO Moberg Pharma
Successful marketing and integration of acquisitions has resulted in double-digit growth in retail sales for our three major brands
Peter Wolpert, CEO of Moberg Pharma
We are highly pleased with the outcome from NAD and we expect the outcome to further strengthen Kerasal Nails® position and growth prospects in the U.S. market
Peter Wolpert, CEO of Moberg Pharma AB
The new organization better reflects the company’s increased focus on the North American market and to progress toward the commercialization of MOB-015, while also enabling synergies in the global sales operations. I would like to thank Martin Ingman for the important work he has done for the company and wish him all the best in the future
Peter Wolpert, CEO of Moberg Pharma AB
Replacing the CRO is a key step in the extensive action program that was recently announced. TFS has the capability to accelerate patient recruitment and finalizing the European study. Combined with the new setup in North America, we are confident in achieving strong Phase 3 results within the timeline
Peter Wolpert, Moberg Pharma’s CEO
MOB-015 is our most valuable pipeline asset and we see a potential to meet the significant unmet needs of patients suffering from nail fungus. The team is working hard to balance a rigorous screening process while maintaining an aggressive timeline for completing the enrollment. The rigorous screening process is instrumental for the outcome of the Phase 3 studies and to achieve strong claims
Peter Wolpert, Moberg Pharma’s CEO
It is a pleasure to welcome Torbjörn to the Management Team at Moberg. I look forward to working together to continue driving the growth of our development programs
Peter Wolpert, CEO of Moberg Pharma AB
This issuance of this patent is an important part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products
Peter Wolpert, Moberg Pharma’s CEO
We are pleased with the agreement with Caret Pharma LLC. which enables us to increase focus on the core Moberg Pharma portfolio. We have now successfully divested both non-core brands included in the acquisition from Prestige Brands, while the acquired strategic brands are developing well
Peter Wolpert, CEO Moberg Pharma
Kerasal Nail® reached a market share of 29%, while at the same time, we have expanded distribution for both Dermoplast® and New Skin®. Enrolment for the MOB-015 study has taken longer than expected but is accelerating after corrective measures have been implemented
Peter Wolpert, CEO Moberg Pharma
The successful results from patients with nail psoriasis, and for the study as a whole, make a stronger selling point for Kerasal Nail®/ Emtrix®, something which is of great importance for future efforts in all markets
Peter Wolpert, CEO of Moberg Pharma
This is our most recent acquisition and we are pleased that the integration is progressing according to plan. The distribution gains provide excellent opportunities to build on the brand equity of Dermoplast® in the years to come
Jeff Vernimb, GM of Moberg Pharma North America
We are excited about the prospects for Zanmira Nail® in Japan, which has the potential to become a major market for Moberg Pharma. We look forward to the continued collaboration with CMIC in Japan, as well as with Menarini in the other markets of the Asia-Pacific region
Peter Wolpert, CEO of Moberg Pharma
The divestment is made for personal financial reasons and I don’t intend to sell additional shares. I have great faith in the prospects for Moberg Pharma and I look forward to continuing to build the company
Peter Wolpert, CEO of Moberg Pharma
We see excellent opportunities to build on the brand equity of New Skin®. This a market leading brand with exciting prospects for growth, as shown with the increased distribution
Jeff Vernimb, GM of Moberg Pharma North America
We highly appreciate the support provided by our bondholders and the large interest for this tap issue. As a result, the issue has been placed at a premium to the nominal amount and we have secured the capital needed to complete the acquisition of DermoPlast®. From January 2017, DermoPlast® is expected to contribute significantly to our profitability and operative cash flow
Peter Wolpert, CEO of Moberg Pharma
I am proud to announce the acquisition of DermoPlast®. After thorough evaluation and diligence I am very pleased that we have now secured financing to be able to complete this important acquisition for Moberg Pharma. The transaction is expected to contribute positively to our sales and profitability and contribute to our long-term financial target to deliver profitable growth and an EBITDA-margin of 25 percent
Peter Wolpert, CEO of Moberg Pharma
The Board of Directors of Moberg Pharma is very pleased with the acquisition of DermoPlast®. Through the acquisition, the company strengthens its portfolio of strategic brands – DermoPlast® fits perfectly into the company's focus on topical products. We can also fully utilize the existing organization and sales channels in the U.S. After the acquisitions, the company now has three major strategic brands – Kerasal Nail®, DermoPlast® and New Skin® – which increases the diversification and thus strengthens the company. The focus over the coming year is to successfully integrate acquisitions and to strengthen the positioning of our portfolio and to continue to create value through the advancement of our development pipeline
Thomas Eklund, chairman of Moberg Pharma
The opportunity to acquire DermoPlast® is very attractive. The acquisition is in line with our strategy and leverages our existing infrastructure and sales channels in the U.S. in an excellent way. DermoPlast® brings increased economies of scale and complements our portfolio with a strong and profitable dermatology brand. We are very pleased with the opportunity to complete this transaction, which is expected to contribute positively to both our sales and profitability and thereby to our long term financial target to deliver profitable growth and an EBITDA margin of 25 per cent
Peter Wolpert, CEO of Moberg Pharma
We appreciate the increased flexibility which our bondholders have granted the company and hence enhanced our possibilities to optimally finance accretive acquisitions
Peter Wolpert, Moberg Pharma’s CEO
We are pleased with the agreement with Strides which enables us to further focus on our strategic assets and M&A activities
Peter Wolpert, CEO Moberg Pharma
We had very positive momentum in Q3. The team has already now delivered on all major milestones for 2016
Peter Wolpert, CEO of Moberg Pharma
This patent provides Moberg with important intellectual property protection for BUPI, our lozenge formulation of bupivacaine for pain management of oral mucositis in cancer patients
Peter Wolpert, CEO of Moberg Pharma
This issuance of this patent is an important milestone for the BUPI development program and part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products.
Peter Wolpert, CEO of Moberg Pharma
The start of the patient enrollment in the Phase 3 program for MOB-015 is a major milestone for Moberg Pharma
Peter Wolpert, CEO of Moberg Pharma
Our long-term vision is to become a global leader in onychomycosis and we believe that MOB-015 has the potential to establish a new standard of care. The Phase 3 studies have been designed to support registration in North America, Europe and other major markets
Peter Wolpert, CEO of Moberg Pharma
This is a significant step forward in the further development of MOB-015. We are committed in our pursuit to bring an efficacious and safe topical treatment in the form of MOB-015 to patients suffering from nail fungus
Kjell Rensfeldt, VP Research and Development of Moberg Pharma AB